×
About 3,871,300 results

ESMO Webinar Series: Managing Patients in the COVID-19 Era
https://www.esmo.org/meetings/esmo-webinar-series/managing-patients-in-the-covid-19-era

Sep 19th, 2020 - This Webinar series has been organised with the aim to share the ESMO adapted recommendations for cancer patient management during the COVID-19 pandemic. These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients.

ESMO Guideline for Cancer Patient Management During the COVID-19 Pandemic
https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic?hit=ehp

Sep 18th, 2020 - These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients. The situation is evolving, and pragmatic actions may be required to deal with the challenges of treating patients, while ensuring their rights, safety and wellbeing.

Neal D. Shore, MD, on Prostate Cancer: Relugolix vs Leuprolide for Advanced Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/neal-shore-on-relugolix-vs-leuprolide-for-advanced-prostate-cancer/

Jun 1st, 2020 - Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and was superior to leuprolide in sustained testosterone suppression, testosterone recovery after discontinuation, and reduction in cardiovascular side effects (Abstract 5602).

NCI director: COVID-19 having ‘profound’ effects on cancer outcomes, research
https://www.healio.com/hematology-oncology/practice-management/news/online/{56279316-24e1-4c34-8527-2538a95b52a9}/nci-director-covid-19-having-profound-effects-on-cancer-outcomes-research

May 30th, 2020 - The oncology community has demonstrated a remarkable ability to adapt amid the COVID-19 pandemic but must be prepared for its long-term effects on cancer care, NCI Director Norman E. “Ned” Sharpless, MD, told ASCO Virtual Scientific Program attendees.

Maintenance PARP-Inhibitor Therapy May Hold Clinically Meaningful Benefits for Women With Recurrent Ovarian Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200191/full/

May 29th, 2020 - The SOLO2 trial found olaparib maintenance therapy may have clinically relevant effects on overall survival (OS) in women with platinum-sensitive relapsed ovarian cancer (PSROC) with BRCA1/2 mutations (Abstract 6002). Andrés Poveda, MD, of Initia Oncology, Hospital Quirónsalud and GEICO, Spain, presented survival and safety outcomes from the trial during the ASCO20 Virtual Scientific Program.

Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd181565
Journal of Parkinson's Disease;

Jul 30th, 2019 - Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of Gocovri® (amantadine) extended release capsules on these episodes.

Considerations for Statin Therapy in Patients with COVID‐19
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262253/
Pharmacotherapy Dashti-Khavidaki

May 4th, 2020 - Statins are well known for their anti‐inflammatory effects, and some hospitals included them in the COVID‐19 treatment protocol. Here, we summarize the main points that should be considered before incorporating this class of drugs in a COVID‐19 treatment regimen.

Levodopa‐induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600052/
Postgraduate Medical Journal;

Jun 5th, 2007 - Levodopa is the most effective drug for treating Parkinson's disease. However, long‐term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa‐induced dyskinesias (LID). The underlying mechanisms f...

Food bioactives, micronutrients, immune function and COVID-19
http://www.isnff-jfb.com/index.php/JFB/article/view/136/236

The development of targeted therapeutics against the novel coronavirus disease 2019 (COVID-19) is highly desirable butmay present a challengein the foreseeable future.Adequate nutrition is a prerequisite of an optimally functioning immune system.Nutritional approaches,including the administration of food bioactives and micronutrients, may therefore have the potential to augmentimmune function a...

Examination of Protein Quantity and Protein Distribution across the Day on Ad Libitum Carbohydrate and Fat Intake in Overweight Women
https://academic.oup.com/cdn/article/1/12/e001933/4772174

The effects of meal-specific protein quantity and protein distribution throughout the day on daily food intake are relatively unknown.

Colchicine as a possible therapeutic option in COVID-19 infection
https://link.springer.com/article/10.1007/s10067-020-05247-5

In contrast, we consider that colchicine can be a good therapeutic option because of several effects in the immunology system involved in SARS-CoV-2 infection and in the acute respiratory distress syndrome (ARDS). Colchicine has effects on the chemotaxis of inflammatory cells such as neutrophils and monocytes and on the intracellular transportation of vesicles such as endosomes and exosomes.

Children and COVID-19: State-Level Data Report
https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/

State-level reports are the best publicly available data on child COVID-19 cases in the United States. The American Academy of Pediatrics and the Children’s Hospital Association are collaborating to collect and share all publicly available data from states on child COVID-19 cases (definition of “child” case is based on varying age ranges reported across states; see report Appendix for details a...

Covid-19: What do we know about “long covid”?
https://www.bmj.com/content/370/bmj.m2815

“Long covid” is a term being used to describe illness in people who have either recovered from covid-19 but are still report lasting effects of the infection or have had the usual symptoms for far longer than would be expected. Many people, including doctors who have been infected, have shared their anecdotal experiences on social media, in the traditional media, and through patients’ groups.

Cancer Pain (PDQ®)–Health Professional Version
https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq?cid=eb_govdel

Pain is one of the most common symptoms in cancer patients and often has a negative impact on patients’ functional status and quality of life. The goal of the following summary is to provide evidence-based, up-to-date, and practical information on the management of cancer pain.

Ultrasound-guided erector spinae plane (ESP) block: A novel intervention for mechanical back pain in the emergency department
https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S1481803518004694

Lower back pain (LBP) is one of the most common health problems worldwide1–3 and is the leading cause of work absenteeism.4 LBP accounts for 3%–4% of all emergency department (ED) presentations,5 and current ED analgesic options include acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids.6, 7 With the current worldwide opioid epidemic and significant opioid-related a...

NHF‐McMaster Guideline on Care Models for Haemophilia Management
http://hemophiliasc.org/wp-content/uploads/2016/06/Guideline-on-Care-Models-for-Hemophilia-Management.pdf
National Hemophilia Foundation-McMaster University

A number of national and international guidance documents have supported integrated care as the optimal model of care for people with hemophilia (PWH). However, the effects of integrated care on patient-important outcomes had not been systematically synthesized or compared to alternative models and questions about the ideal composition of services and providers for optimal hemophilia care ...

Framework for Healthcare Systems Providing Non-COVID-19 Clinical Care During the COVID-19 Pandemic
https://www.cdc.gov/coronavirus/2019-ncov/hcp/framework-non-COVID-care.html
CDC

At the onset of the COVID-19 pandemic, CDC recommended that healthcare systems prioritize urgent visits and delay elective care to mitigate the spread of COVID-19 in healthcare settings. A consequence of the pandemic has been the under-utilization of important medical services for patients with non-COVID-19-related urgent and emergent health needs [1-3]. As the pandemic continues, healthcare sy...

COVID-19 in Racial and Ethnic Minority Groups
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html
CDC

The effects of COVID-19 on the health of racial and ethnic minority groups is still emerging; however, current data suggest a disproportionate burden of illness and death among racial and ethnic minority groups. A recent CDC MMWR report included race and ethnicity data from 580 patients hospitalized with lab-confirmed COVID-19 found that 45% of individuals for whom race or ethnicity data was av...

COVID-19 Behavioral Health Resources
https://asprtracie.hhs.gov/technical-resources/115/covid-19-behavioral-health-resources/99

The federal government is taking steps to protect American’s physical and behavioral health in response to the 2019 Novel Coronavirus pandemic. The resources in this collection were created by federal agencies and their partners to help healthcare providers, caregivers, and the general population prepare for and manage the negative behavioral effects that can accompany a public health emergency.

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
https://link.springer.com/article/10.1007/s00406-019-00982-6
European Archives of Psychiatry and Clinical Neuroscience;

Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is limited in ...